Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASH 2018

CLL

View all
Venetoclax and bendamustine plus rituximab or obinutuzumab for CLL
Stephan Stilgenbauer • 1 Dec 2018
Ibrutinib emerging as the new standard of care for frontline elderly CLL: ALLIANCE results
Jennifer Woyach • 2 Dec 2018

Multiple Myeloma

View all
Quadruplet regimens for newly diagnosed myeloma & MRD-tracking of DKRd-treated patients
Ola Landgren • 2 Dec 2018
Ixazomib prolongs PFS following ASCT in newly diagnosed myeloma
Vincent Rajkumar • 2 Dec 2018

Waldenström’s

View all
Association between depth of response and survival in Waldenström’s
Jonas Paludo • 6 Dec 2018
Mass spectrometry-flow cytometry study of IgM MGUS progression to Waldenström’s
Jonas Paludo • 6 Dec 2018

AML

View all
1:57
An update on AMG 330: can BiTEs be as successful in AML as ALL?
Marion Subklewe • 2 Dec 2018
1:15
E-selectin antagonist uproleselan for R/R AML: efficacy and safety data
Daniel DeAngelo • 2 Dec 2018

Lymphoma

View all
5:51
Updated JULIET results for tisagenlecleucel in DLBCL
Richard Thomas Maziarz • 1 Dec 2018
1:23
R2 in the second-line: lenalidomide-rituximab improves PFS in relapsed/refractory NHL
Ian Flinn • 2 Dec 2018

ALL

View all
1:14
Initial data for CAR T-cell product JCAR021 in ALL and B-cell lymphoma
Jordan Gauthier • 2 Dec 2018
6:20
Updated pivotal ELIANA study results for CAR T-cell product tisagenlecleucel in ALL
Stephan Grupp • 4 Dec 2018

Sickle Cell Disease & β-Thalassemia

View all
7:08
BELIEVE: β-thalassemia treatment with luspatercept reduces transfusion burden
Maria Domenica Cappellini • 2 Dec 2018
7:37
Opioid use in sickle cell is not associated with in-hospital mortality in the US
Oladimeji Akinola Akinboro • 2 Dec 2018

Trial Updates

View all
Updates from MURANO for CLL: time-limited VenR & impact of MRD
John Seymour • 3 Dec 2018
4:40
Reduced R-CHOP in favourable-prognosis DLBCL doesn’t compromise outlook
Viola Poeschel • 3 Dec 2018

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals